Johnson & Johnson (JNJ) Net Cash Flow (2009 - 2026)
Johnson & Johnson (JNJ) posted Net Cash Flow of $2.0 billion for Q1 2026, up 37.73% sequentially from $1.5 billion in Q4 2025, and down 85.99% YoY from $14.3 billion in Q1 2025.
Johnson & Johnson (JNJ) Net Cash Flow (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Net Cash Flow data on file, last reported at $2.0 billion in Q1 2026.
- Quarterly Net Cash Flow fell 85.99% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.9 billion (down 229.0% YoY) and the FY2025 annual result came in at -$4.6 billion, down 281.34% from the prior year.
- Net Cash Flow climbed to $2.0 billion in Q1 2026 per JNJ's latest filing, from $1.5 billion in the prior quarter.
- The five-year high for Net Cash Flow was $14.3 billion in Q1 2025, with the low at -$20.1 billion in Q2 2025.
- Average Net Cash Flow over 5 years is -$3.1 million, with a median of -$300.0 million recorded in 2025.
- Year-over-year, Net Cash Flow jumped 414.6% in 2023 and tumbled 3831.57% in 2025.
- Johnson & Johnson's Net Cash Flow stood at -$4.0 billion in 2022, then soared by 149.65% to $2.0 billion in 2023, then jumped by 115.5% to $4.3 billion in 2024, then tumbled by 66.34% to $1.5 billion in 2025, then soared by 37.73% to $2.0 billion in 2026.
- Business Quant data shows JNJ's Net Cash Flow at $2.0 billion in Q1 2026, $1.5 billion in Q4 2025, and -$300.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -2.05 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.17 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -1.53 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 392.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.00 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Dec 28, 2025 | 1.46 Bn |
| Dec 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | -300.00 Mn |
| Sep 28, 2025 | -300.00 Mn |
| Jun 29, 2025 | -20.05 Bn |
| Jun 29, 2025 | -20.05 Bn |
| Mar 30, 2025 | 14.30 Bn |
| Mar 30, 2025 | 14.30 Bn |
| Dec 29, 2024 | 4.32 Bn |
| Dec 29, 2024 | 4.32 Bn |
| Sep 29, 2024 | -5.02 Bn |
| Sep 29, 2024 | -5.02 Bn |
| Jun 30, 2024 | -510.00 Mn |
| Jun 30, 2024 | -510.00 Mn |
| Mar 31, 2024 | 3.74 Bn |
| Mar 31, 2024 | 3.74 Bn |
| Dec 31, 2023 | 2.01 Bn |
| Dec 31, 2023 | 2.01 Bn |